References
- Armstrong-James D, Meintjes G, Brown GD. A neglected epidemic: fungal infections in HIV/AIDS. Trends Microbiol. 2014;22(3):120–127.
- Perfect JR. “Is there an emerging need for new antifungals?” Expert opin. Emerg Drugs. 2016;21(2):129–131.
- Kontoyiannis DP. Antifungal resistance: an emerging reality and a global challenge. J Infect Dis. 2017;216(3):S431–S435.
- Krysan DJ. Toward improved anti-cryptococcal drugs: novel molecules and repurposed drugs. Fungal Genet Biol. 2015;78:93–98.
- Rajasingham R, Smith RM, Park BJ, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17(8):873–881.
- Liu X-Z, Wang Q-M, Göker M, et al. Towards an integrated phylogenetic classification of the Tremellomycetes. Stud Mycol. 2015;81:85–147.
- Perfect JR. The antifungal pipeline: a reality check. Nat Rev Drug Discov. 2017;16(9):603–616.
- Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis. 1990;12(2):308–329.
- Nett JE, Andes DR. Antifungal agents: spectrum of activity, pharmacology, and clinical indications. Infect Dis Clin NA. 2016;30(1):53–83.
- Richardson K. The discovery of fluconazole. Contemp Org Synth. 1996;3:125–132.
- Rodrigues ML. Funding and innovation in diseases of neglected populations: the paradox of cryptococcal meningitis. PLoS Negl Trop Dis. 2016;10(3):e0004429.
- Stone NRH, Bicanic T, Salim R, et al. Liposomal Amphotericin B (AmBisome(®)): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions. Drugs. 2016;76(4):485–500.
- Sionov E, Lee H, Chang YC, et al. Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes. PLoS Pathog. 2010;6(4):e1000848.
- Vermes A, H-J G, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother. 2000;46(2):171–179.
- Denning DW, Bromley MJ. Infectious Disease. How to bolster the antifungal pipeline. Science (80). 2015;347:1414–1416.
- Nyazika TK, Hagen F, Machiridza T, et al. Cryptococcus neoformans population diversity and clinical outcomes of HIV-associated cryptococcal meningitis patients in Zimbabwe. J Med Microbiol. 2016;65(11):1281–1288.
- Nishikawa H, inventor; Toyama Chemical Co Ltd, assignee. Pharmaceutical composition comprising phenylamidine derivative and method of using the pharmaceutical composition in combination with antifungal agent. US8173157. 2010 Apr 22.
- Chen Y, inventor; Chen Y, assignee. Method and preparations for the treatment of fungus. US6090389. 2000 Jul 18.
- Kwang Sik K, inventor; Univ Johns Hopkins, assignee. Methods for treating or preventing brain infections. WO2009152454. 2009 Dec 17.
- Napoletano M, Fraire C, Albini E, et al., inventor; Zambon spa, Isagro spa, assignee. Azole compounds endowed with antimycotic activity for human and veterinary use. WO9731903. 1997 Sep 04.
- Bartizal KF, Abruzzo GK, Flattery AM, inventor; Merck & Co inc, assignee. Antifungal combination therapy. WO9810782. 1998 Mar 19.
- Nishikawa H, Nomura N, Fujino N, inventor; Toyama Chemical Co Ltd, assignee. Pharmaceutical composition and method using antifungal agent in combination. US8993603. 2009 Apr 02.
- Del Poeta M, Mor V, inventor; Research Foundation of Suny, assignee. Anti-fungals targeting the synthesis of fungal sphingolipids. WO201694307. 2018 May 24.
- Nosanchuk J, Casadevall A, Ovalle R, inventor; Einstein Coll Med, assignee. Method for inhibiting melanogenesis and uses thereof. US6509325. 2003 Jan 21.
- Dadachova E, Casadevall A, Nazouki A, inventor; Albert Einstein College of Medicine of Yeshiva University, assignee. Methods of applying ionization radiation for therapy of infections. US7651689. 2010 Jan 26.
- Hussell T, Snellgrove R, inventor; Imp Innovations Ltd, assignee. Compositions and methods relating to manipulation of the myeloid immune compartment during respiratory infection. WO2009004339. 2009 Oct 22.
- Hussel T, Humphreys I, inventor; Imp Innovations Ltd, assignee. Uses of agents that bind immune system components. WO03026693. 2003 Dec 18.
- Amplyx Pharmaceuticals Highlights Phase 1 APX001 Data at IDWeek 2017 – amplyx [Internet]. cited 2018 Apr 20. Available from: https://amplyx.com/amplyx-pharmaceuticals-highlights-phase-1-apx001-data-at-idweek-2017/.
- Amplyx – advancing novel therapeutic solutions for life-threatening fungal infections. [Internet]. cited 2018 Apr 20. Available from: https://amplyx.com/#focus.
- Amplyx pharmaceuticals receives fourth “qualified infectious disease product” (qidp) designation from the fda for apx001 – amplyx [internet]. cited 2018 Apr 20. Available from: https://amplyx.com/amplyx-pharmaceuticals-receives-fourth-qualified-infectious-disease-product-qidp-designation-from-the-fda-for-apx001/.
- Schell WA, Giamberardino C, Shaw KJ, et al. Efficacy of oral apx001 in a murine model of cryptococcal meningitis. Open Forum Infect Dis. 2017;4(1):S478–S478.
- Zhao M, Lepak AJ, VanScoy B, et al. In vivo pharmacokinetics and pharmacodynamics of apx001 against candida spp. in a neutropenic disseminated candidiasis mouse model. Antimicrob Agents Chemother. 2018;62:e02542–17.
- Hager CL, Larkin EL, Long L, et al. In vitro and in vivo evaluation of the antifungal activity of APX001A/APX001 against Candida auris. Antimicrob Agents Chemother. 2018;62(4):e02319–17.
- Wellstat therapeutics corporation | wt39006 - antifungal [internet]. cited 2017 Nov 28. Available from: https://www.wellstattherapeutics.com/therapeutics/html/randd/compounds/WT39006.html.
- AmtixBio – advanced microbial technologies and biotics [internet]. cited 2018 Apr 20. Available from: http://amtixbio.com/.
- AmtixBio amtixBio aims to develop novel natural antimicrobial products and diverse microbial biomaterials through molecular biological and genetic approaches [internet]. cited 2018 Apr 20. Available from: http://amtixbio.com/wp-content/uploads/2017/06/Anti-microbial-LactobacillusAMTIXBIO.pdf.
- NovaBiotics receives most innovative eu biotech sme 2017 award | scottish lifesciences association [internet]. cited 2018 Apr 20. Available from: https://www.scottishlifesciencesassociation.org.uk/news/-novabiotics-receives-most-innovative-eu-biotech-sme-2017-award/.
- Novamycin NP339 - novabiotics [internet]. cited 2017 Nov 28. Available from: https://www.novabiotics.co.uk/pipeline/novamycin-np339.
- Novamycin (NP339) | aspergillus & aspergillosis website [internet]. cited 2018 Apr 23. Available from: https://www.aspergillus.org.uk/content/novamycin-np339.
- NovaBiotics announces first patients dosed in lynovex clinical study - novabiotics [internet]. cited 2017 Nov 28. Available from: https://www.novabiotics.co.uk/news/novabiotics-announces-first-patients-dosed-in-lynovex-clinical-study.
- Wiederhold N. Antifungal resistance: current trends and future strategies to combat. Infect Drug Resist. 2017;10:249–259.
- Wiederhold NP, Najvar LK, Fothergill AW, et al. The novel arylamidine T-2307 maintains in vitro and in vivo activity against echinocandin-resistant Candida albicans. Antimicrob Agents Chemother. 2015;59(2):1341–1343.
- Wiederhold NP, Najvar LK, Fothergill AW, et al. The novel arylamidine T-2307 demonstrates in vitro and in vivo activity against echinocandin-resistant Candida glabrata. J Antimicrob Chemother. 2016;7(3):692–695.
- Mitsuyama J, Nomura N, Hashimoto K, et al. in vitro and in vivo antifungal activities of t-2307, a novel arylamidine. Antimicrob Agents Chemother. 2008;52(4):1318–1324.
- Nishikawa H, Fukuda Y, Mitsuyama J, et al. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen. J Antimicrob Chemother. 2017;72(6):1709–1713.
- Muñoz M, Camargo M, Ramírez JD. Estimating the intra-taxa diversity, population genetic structure, and evolutionary pathways of cryptococcus neoformans and cryptococcus gattii. Front Genet. 2018;9:148.
- Infectious field | toyama chemical [internet]. cited 2017 Nov 28. Available from: https://www.toyama chemical.co.jp/en/rd/area/infection.html.
- iNtODEWORLD | opening new era in anti-fugal agent (iN-EYD34) [Internet]. cited 2017 Nov 27. Available from: http://intodeworld.com/opening-new-era-in-anti-fugal-agent-in-eyd34/.
- Hargrove TY, Garvey EP, Hoekstra WJ, et al. Crystal structure of the new investigational drug candidate vt-1598 in complex with aspergillus fumigatus sterol 14α-demethylase provides insights into its broad-spectrum antifungal activity. Antimicrob Agents Chemother. 2017;61:e00570–17.
- Viamet group [internet]. cited 2018 May 4. Available from: http://www.viamet.com/index.php.
- Wiederhold NP, Patterson HP, Tran BH, et al. Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus. J Antimicrob Chemother. 2018;73(2):404–408.
- Wiederhold NP, Shubitz LF, Najvar LK, et al. The novel fungal cyp51 inhibitor vt-1598 is efficacious in experimental models of central nervous system coccidioidomycosis caused by coccidioides posadasii and coccidioides immitis. Antimicrob Agents Chemother. 2018;62(4):e02258–17.
- FDA grants fast track designation to vt-1598 for treatment of valley fever | business wire [internet]. cited 2018 May 4. Available from: https://www.businesswire.com/news/home/20170713005097/en/FDA-Grants-Fast-Track-Designation-VT-1598-Treatment.
- MYC-053 – TGV-Therapeutics [Internet]. cited 2018 Jul 13. Available from: http://tgvtherapeutics.com/the-science/myc-053.html.
- Matinas biopharma to present positive preclinical data of mat2203 at the 28th european congress of clinical microbiology and infectious disease :: matinas biopharma holdings, inc. (MTNB) [Internet]. cited 2018 May 7. Available from: https://www.matinasbiopharma.com/media/press-releases/detail/308/matinas-biopharma-to-present-positive-preclinical-data-of.
- MAT2203: encochleated Formulation of Amphotericin B :: matinas biopharma holdings, inc. (MTNB) [Internet]. cited 2018 May 4. Available from: https://www.matinasbiopharma.com/pipeline/mat2203-encochleated-formulation-of-amphotericin-b.
- Efficacy of oral encochleated amphotericin b (camb) in a mouse model of cryptococcal meningeoencephalitis [internet]. cited 2018 May 4. Available from: http://www.abstractsonline.com/pp8/#!/4358/presentation/6632.
- Koselny K, Green J, DiDone L, et al. The celecoxib derivative ar-12 has broad-spectrum antifungal activity in vitro and improves the activity of fluconazole in a murine model of cryptococcosis. Antimicrob Agents Chemother. 2016;60(12):7115–7127.
- Koselny K, Green J, Favazzo L, et al. Antitumor/antifungal celecoxib derivative ar-12 is a non-nucleoside inhibitor of the anl-family adenylating enzyme acetyl coa synthetase. ACS Infect Dis. 2016;2(4):268–280.
- Booth L, Roberts JL, Ecroyd H, et al. AR-12 inhibits multiple chaperones concomitant with stimulating autophagosome formation collectively preventing virus replication. J Cell Physiol. 2016;23(10):2286–2302.
- Arno therapeutics receives european orphan drug designation for ar-12 to treat two infectious diseases otcbb:arni [internet]. cited 2018 Apr 20. Available from: https://globenewswire.com/news-release/2015/04/30/730727/10131284/en/Arno-Therapeutics-Receives-European-Orphan-Drug-Designation-for-AR-12-to-Treat-Two-Infectious-Diseases.html.
- Arno therapeutics announces plans to dissolve | business wire [internet]. cited 2018 Apr 20. Available from: https://www.businesswire.com/news/home/20171222005260/en/Arno-Therapeutics-Announces-Plans-Dissolve.
- Lass‐Flörl C, Dierich MP, Fuchs D, et al. Antifungal activity against candida species of the selective serotonin‐reuptake inhibitor, sertraline. Clin Infect Dis. 2001;33(12):e135–e136.
- Lass-Flörl C, Dierich MP, Fuchs D, et al. Antifungal properties of selective serotonin reuptake inhibitors against Aspergillus species in vitro. J Antimicrob Chemother. 2001;48(6):775–779.
- Zhai B, Wu C, Wang L, et al. The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections. Antimicrob Agents Chemother. 2012;56(7):3758–3766.
- Treviño-Rangel RDJ, Villanueva-Lozano H, Hernández-Rodríguez P, et al. Activity of sertraline against Cryptococcus neoformans : in vitro and in vivo assays. Med Mycol. 2016;54(3):280–286.
- Heller I, Leitner S, Dierich MP, et al. Serotonin (5-HT) enhances the activity of amphotericin B against Aspergillus fumigatus in vitro. Int J Antimicrob Agents. 2004;24(4):401–404.
- Ayaz M, Subhan F, Ahmed J, et al. Sertraline enhances the activity of antimicrobial agents against pathogens of clinical relevance. J Biol Res. 2015;22(1):4.
- Rossato L, Loreto ÉS, Zanette RA, et al. In vitro synergistic effects of chlorpromazine and sertraline in combination with amphotericin B against Cryptococcus neoformans var. grubii. Folia Microbiol. 2016;61(5):399–403. (Praha).
- Rhein J, Morawski BM, Hullsiek KH, et al. Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study. Lancet Infect Dis. 2016;16(7):809–818.
- Villanueva-Lozano H, Treviño-Rangel RDJ, González GM, et al. Clinical evaluation of the antifungal effect of sertraline in the treatment of cryptococcal meningitis in HIV patients: a single Mexican center experience. Infection. 2018;46(1):25–30.
- Chapman N, Doubell A, Oversteegen L, et al. Neglected disease research and development: reflecting on a decade of global investment. Policy Cures Research; 2017 (G-finder report, Year 10).
- Molloy SF, Chiller T, Greene GS, et al. Cryptococcal meningitis: A neglected NTD? PLoS Negl. Trop Dis. 2017;11(6):e0005575.
- Rodrigues ML. Neglected disease, neglected populations: the fight against Cryptococcus and cryptococcosis. Mem Inst Oswaldo Cruz. 2018;113:7.
- Williamson PR. The relentless march of cryptococcal meningitis. Lancet Infect Dis. 2017;17(8):790–791.
- Ostermann H, Solano C, Jarque I, et al. Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain. BMC Pharmacol Toxicol. 2014;15:52.
- Bongomin F, Oladele RO, Gago S, et al. A systematic review of fluconazole resistance in clinical isolates of Cryptococcus species. Mycoses. 2018;61(5):290–297.
- StatPlanet [Internet]. cited 2018 May 22. Available from: https://www.fungalinfectiontrust.org/stat planet 5FC/web/StatPlanet.html.
- Butts A, Koselny K, Chabrier-Roselló Y, et al. Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo. MBio. 2014;5(1):e00765–13.
- Albuquerque PC, Rodrigues ML. Research trends on pathogenic Cryptococcus species in the last 20 years: a global analysis with focus on Brazil. Future Microbiol. 2012;7(3):319–329.
- Zheng W, Sun W, Simeonov A. Drug repurposing screens and synergistic drug-combinations for infectious diseases. Br J Pharmacol. 2018;175(2):181–191.
- Cha Y, Erez T, Reynolds IJ, et al. Drug repurposing from the perspective of pharmaceutical companies. Br J Pharmacol. 2018;175(2):168–180.
- Truong M, Monahan LG, Carter DA, et al. Repurposing drugs to fast-track therapeutic agents for the treatment of cryptococcosis. PeerJ. 2018;6:e4761.
- Nixon GL, McEntee L, Johnson A, et al. Repurposing and reformulation of the antiparasitic agent flubendazole for treatment of cryptococcal meningoencephalitis, a neglected fungal disease. Antimicrob Agents Chemother. 2018;62(4):e01909–17.
- Ogundeji AO, Pohl CH, Sebolai OM. The repurposing of anti-psychotic drugs, quetiapine and olanzapine, as anti-cryptococcus drugs. Front Microbiol. 2017;8:815.
- Joffe LS, Schneider R, Lopes W, et al. The anti-helminthic compound mebendazole has multiple antifungal effects against cryptococcus neoformans. Front Microbiol. 2017;8:535.
- Thangamani S, Maland M, Mohammad H, et al. Repurposing approach identifies auranofin with broad spectrum antifungal activity that targets mia40-erv1 pathway. Front Cell Infect Microbiol. 2017;7:4.
- Thangamani S, Eldesouky HE, Mohammad H, et al. Ebselen exerts antifungal activity by regulating glutathione (GSH) and reactive oxygen species (ROS) production in fungal cells. Biochim Biophys Acta Gen Subj. 2017;1861:3002–3010.